-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $280

Benzinga·07/07/2026 15:59:13
Listen to the news
RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $275 to $280.